Conatus Pharmaceuticals Inc (NASDAQ:CNAT)‘s stock had its “buy” rating reaffirmed by research analysts at Brean Capital in a research note issued on Thursday, Market Beat.com reports. They currently have a $13.00 price objective on the biotechnology company’s stock.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) belongs to Healthcare sector. Its weekly performance is -5.82%. On last trading day company shares ended up at $1.78.
Board of Directors of Navios Acquisition Corporation (NYSE:NNA) declared a quarterly cash dividend for the fourth quarter of 2015 of $0.05 per share of common stock. The dividend is payable on March 23, 2016 to stockholders of record as of March 17, 2016 and provides a current yield of 10.5%.
Navios Maritime Acquisition Corporation (NYSE:NNA) shares decreased -6.08% in last trading session and ended the day at $1.70. NNA Gross Margin is 98.20% and its return on assets is 5.40%. Navios Maritime Acquisition Corporation (NYSE:NNA) quarterly performance is -48.17%.
The Board of Directors of Emclaire Financial Corp (NASDAQ:EMCF), the parent holding company of the Farmers National Bank of Emlenton, declared a quarterly cash dividend on February 17, 2016 of $0.26 per common share payable on March 18, 2016, to shareholders of record on March 1, 2016.
On 25 February, Emclaire Financial Corp. (NASDAQ:EMCF) shares remains unchanged and was closed at $23.39. EMCF EPS growth in last 5 year was 22.40%. Emclaire Financial Corp. (NASDAQ:EMCF) year to date (YTD) performance is -2.54%.
On 23 February, Verisk Analytics, Inc. (NASDAQ:VRSK) reported Total revenue grew 20.6% in the fourth quarter and 18.4% for fiscal year 2015; organic revenue growth was 3.9% in the fourth quarter and 7.4% for fiscal year 2015, excluding recent acquisitions and pass-through healthcare revenue.
Verisk Analytics, Inc. (NASDAQ:VRSK) ended the last trading day at $73.90. Company weekly volatility is calculated as 2.94% and price to cash ratio as 72.63. Verisk Analytics, Inc. (NASDAQ:VRSK) showed a weekly performance of 7.96%.
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) reported Net income for the fourth quarter was $1.2 million, or $0.08 per basic share and $0.07 per diluted share, compared to a net loss of $5.5 million, or $0.39 per basic and diluted share in the three months ended December 31, 2014.
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares advanced 9.60% in last trading session and ended the day at $66.30. EGRX Gross Margin is 67.40% and its return on assets is -4.00%. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) quarterly performance is -19.72%.